Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call Transcript
Operator: Good morning. My name is Nadia, and I'll be your conference operator today.
Blueprint Medicines Corp (BPMC)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Polar Capital Brian Ashford-Russell And Tim Woolley | 877,005 | $81,122,963 | +1% | 0.38% |
| 2. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 768,776 | $71,111,780 | -69% | 2.31% |
| 3. | Alkeon Capital Management Panayotis Takis Sparaggis | 718,928 | $66,500,841 | -20% | 0.11% |
| 4. | Millennium Management Israel Englander | 618,787 | $57,237,798 | -2% | 0.02% |
| 5. | GLG Partners Noam Gottesman | 518,616 | $47,971,980 | +32% | 0.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.98 | 1,100 | 92,281 | 2022-11-03 | Filing | ||
| $82.66 | 10 | 5,822 | 2021-07-13 | Filing | ||
| $59.98 | 5,000 | 10,812 | 2022-03-03 | Filing | ||
| $18.00 | 125,000 | Large Shareholder, Other | 2,500,711 | 2015-05-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $91.96 | 2,100 | 157,557 | 2024-12-19 | Filing | ||
| $91.15 | 3,800 | 159,657 | 2024-12-19 | Filing | ||
| $89.01 | 5,180 | 163,457 | 2024-12-19 | Filing | ||
| $88.28 | 3,920 | 168,637 | 2024-12-19 | Filing | ||
| $96.50 | 108 | 69,383 | 2024-12-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,584,176 | $607,324,394 | 0.01% | |
| 2. | 6,114,970 | $564,044,833 | 0.01% | |
| 3. | 4,348,311 | $401,088,207 | 0.03% | |
| 4. | 4,276,333 | $394,448,956 | 0.07% | |
| 5. | 2,424,200 | $223,608,208 | 0.01% |
News See All
Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2024 Earnings Call Transcript August 1, 2024Blueprint Medicines Corporation beats earnings expectations.
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript
Blueprint Medicines Corporation misses on earnings expectations. Reported EPS is $ EPS, expectations were $-1.64.
Insiders Are Dumping These 10 Healthcare Stocks
In this article, we will take a detailed look at Insiders Are Dumping These 10 Healthcare Stocks. For a quick overview of such stocks, read our article Insiders Are Dumping These 5 Healthcare Stocks...
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Call Transcript
Blueprint Medicines Corporation beats earnings expectations. Reported EPS is $-1.82, expectations were $-2.04.
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Call Transcript
Blueprint Medicines Corporation beats earnings expectations. Reported EPS is $-1.82, expectations were $-2.04.
12 Best Genomics Stocks To Buy Now
In this piece, we will take a look at the 12 best genomics stocks to buy now.
5 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts
In this article, we discuss the 5 stocks receiving a massive vote of approval from Wall Street analysts.
Top 20 Genomics Companies in the World
In this piece, we will take a look at the top 20 genomics companies in the world.